{"id":"eligard-tm","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Hot flashes"},{"rate":"20–40","effect":"Fatigue"},{"rate":"40–60","effect":"Erectile dysfunction"},{"rate":"40–60","effect":"Decreased libido"},{"rate":"5–15","effect":"Injection site reaction"},{"rate":"10–20","effect":"Gynecomastia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist that initially stimulates the pituitary gland but with continuous exposure causes downregulation of GnRH receptors, resulting in sustained suppression of gonadal hormone secretion. This leads to castration-level testosterone suppression, which is the therapeutic goal in hormone-sensitive prostate cancer. Eligard is a sustained-release formulation designed to provide continuous drug delivery over weeks to months.","oneSentence":"Eligard is a leuprolide acetate depot injection that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:19.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Prostate cancer requiring androgen deprivation therapy"}]},"trialDetails":[{"nctId":"NCT01136226","phase":"PHASE4","title":"Evaluate Recovery of Testosterone for Patients Using Eligard","status":"COMPLETED","sponsor":"Chesapeake Urology Research Associates","startDate":"2003-10","conditions":"Prostate Cancer","enrollment":42}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL DISCOMFORT"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BALANCE DISORDER"},{"count":1,"reaction":"THERAPY INTERRUPTED"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Eligard (TM)","genericName":"Eligard (TM)","companyName":"Chesapeake Urology Research Associates","companyId":"chesapeake-urology-research-associates","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eligard is a leuprolide acetate depot injection that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone production. Used for Advanced prostate cancer, Prostate cancer requiring androgen deprivation therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}